6CQ Stock Chart & Stats
€0.57
-€0.02(-4.01%)
At close: 4:00 PM EDT
€0.57
-€0.02(-4.01%)
Day’s Range― - ―
52-Week Range€0.48 - €1.90
Previous CloseN/A
Volume91.00
Average Volume (3M)703.00
Market Cap
€256.89M
Enterprise Value€1.05K
Total Cash (Recent Filing)€63.62M
Total Debt (Recent Filing)€587.20M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding354,225,600
10 Day Avg. Volume609
30 Day Avg. Volume703
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.22
Price to Sales (P/S)0.62
P/FCF Ratio10.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.59Price Target Upside179.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)€406.91M
Bulls Say, Bears Say
Bulls Say
EarningsBetter-than-expected gross margins driving EBITDA slightly ahead of forecast.
Financial PerformanceAdjusted EBITDA of $39.8M was above the estimate of $36.0M.
International ExpansionCresco announced that it will be entering international markets with plans to launch its branded flower into Germany.
Bears Say
Margin ExpectationsManagement expects margins to return to Q1 levels for the second half of the year.
Revenue DeclineRevenue of $163.6M was down 1.3% sequentially and down 11.2% year-over-year.
Cresco Labs News
6CQ FAQ
What was Cresco Labs’s price range in the past 12 months?
Cresco Labs lowest stock price was €0.47 and its highest was €1.90 in the past 12 months.
What is Cresco Labs’s market cap?
Cresco Labs’s market cap is €256.89M.
When is Cresco Labs’s upcoming earnings report date?
Cresco Labs’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Cresco Labs’s earnings last quarter?
Currently, no data Available
Is Cresco Labs overvalued?
According to Wall Street analysts Cresco Labs’s price is currently Undervalued.
Does Cresco Labs pay dividends?
Cresco Labs does not currently pay dividends.
What is Cresco Labs’s EPS estimate?
Cresco Labs’s EPS estimate is -0.01.
How many shares outstanding does Cresco Labs have?
Cresco Labs has 354,225,600 shares outstanding.
What happened to Cresco Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cresco Labs?
Currently, no hedge funds are holding shares in DE:6CQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cresco Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.59 (179.62% Upside)
€1.59 (179.62% Upside)
Blogger Sentiment
Bullish
DE:6CQ Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €52.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.11%
Trailing 12-Months
Company Description
Cresco Labs
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
6CQ Company Deck
6CQ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management delivered solid Q1 margins and EBITDA from a streamlined cost structure, achieved meaningful operational and licensing wins (PA store expansion, Ohio openings, Kentucky harvest, Texas license) and provided constructive Q2 growth guidance (~+10% revenue). Offsets include near-term revenue headwinds from the planned California exit and Michigan excise tax, ongoing pricing compression, seasonal cash flow timing, and unresolved regulatory details around rescheduling (including the scope and timing of 280E relief). On balance, operational momentum, accretive M&A activity, and licensing progress outweigh the short-term market and regulatory challenges.View all DE:6CQ earnings summaries6CQ Stock 12 Month Forecast
Average Price Target
€1.59
▲(179.62% Upside)